CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Overview
Authors
Affiliations
Although human genetics has resulted in the identification of novel lipid-related genes that can be targeted for the prevention of atherosclerotic vascular disease, medications targeting these genes or their protein products have short-term effects and require frequent administration during the course of the lifetime for maximal benefit. Genome-editing technologies, such as CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9) have the potential to permanently alter genes in the body and produce long-term and even lifelong protection against atherosclerosis. In this review, we discuss recent advances in genome-editing technologies and early proof-of-concept studies of somatic in vivo genome editing in mice that highlight the potential of genome editing to target disease-related genes in patients, which would establish a novel therapeutic paradigm for atherosclerosis.
Vascular Extracellular Matrix in Atherosclerosis.
Di Nubila A, Dilella G, Simone R, Barbieri S Int J Mol Sci. 2024; 25(22).
PMID: 39596083 PMC: 11594217. DOI: 10.3390/ijms252212017.
Emerging Therapeutic Strategies in Cardiovascular Diseases.
Singh R, Chandi S, Sran S, Aulakh S, Nijjar G, Singh K Cureus. 2024; 16(7):e64388.
PMID: 39131016 PMC: 11317025. DOI: 10.7759/cureus.64388.
What did CRISPR-Cas9 accomplish in its first 10 years?.
Khlidj Y Biochem Med (Zagreb). 2023; 33(3):030601.
PMID: 37545694 PMC: 10373057. DOI: 10.11613/BM.2023.030601.
Gene editing for dyslipidemias: New tools to "cut" lipids.
Stankov S, Cuchel M Atherosclerosis. 2023; 368:14-24.
PMID: 36725417 PMC: 10493168. DOI: 10.1016/j.atherosclerosis.2023.01.010.
Prospective Advances in Genome Editing Investigation.
Isola G Adv Exp Med Biol. 2022; 1396:301-313.
PMID: 36454474 DOI: 10.1007/978-981-19-5642-3_19.